Product Information
DEXTROAMP-AMPHETAMIN 10 MG TAB is a generic product labeled by Glenmark Pharmaceuticals Inc., USA, priced at $0.2327 per EA under NDC 68462064901. Its NADAC has been published 67 times since Jun 25, 2025.
FDA first approved this application on Jul 5, 2022. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
DEXTROAMP-AMPHETAMIN 10 MG TAB
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine SulfateStrength
2.5; 2.5; 2.5; 2.5 mg/1; mg/1; mg/1; mg/1
Manufacturer
Glenmark Pharmaceuticals Inc., USANDC
68462064901
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
AMPHETAMINE DL-ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATEApproval Type
Generic (ANDA)
FDA Application
ANDA210754FDA Approved
7/5/2022
TE Code
AB
On Market Since
5/12/2025
Pharmacological Classes
Price Statistics
The NADAC for DEXTROAMP-AMPHETAMIN 10 MG TAB has been published 67 times since Jun 25, 2025, and over the history we have for it it has declined 19.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2327 per EA |
|---|---|
| All-time high | $0.2883 (Jul 16, 2025) |
| All-time low | $0.2327 (Sep 23, 2026) |
| 52-week high | $0.2513 |
| 52-week low | $0.2327 |
| Median price | $0.2426 |
| Average price | $0.2459 |
| Largest weekly change | -8.9% (Sep 17, 2025) |
| Weeks tracked | 67 |
| Tracking since | Jun 25, 2025 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Glenmark Pharmaceuticals Inc., USA manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Central Nervous System Stimulant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DEXTROAMP-AMPHETAMIN 10 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for DEXTROAMP-AMPHETAMIN 10 MG TAB, manufactured by Glenmark Pharmaceuticals Inc., USA, is $0.2327 per EA (NDC 68462064901), effective Sep 30, 2026.
How has the price of DEXTROAMP-AMPHETAMIN 10 MG TAB changed over time?
Over the history we have for it, the NADAC for DEXTROAMP-AMPHETAMIN 10 MG TAB has declined 19.3%. It has been tracked across 67 weekly CMS publications since Jun 25, 2025.
What are the highest and lowest recorded NADAC prices for DEXTROAMP-AMPHETAMIN 10 MG TAB?
Since Jun 25, 2025, the NADAC for DEXTROAMP-AMPHETAMIN 10 MG TAB has ranged from a low of $0.2327 (Sep 23, 2026) to a high of $0.2883 (Jul 16, 2025), with a median of $0.2426 per EA.
Are there cheaper alternatives to DEXTROAMP-AMPHETAMIN 10 MG TAB?
No other NADAC-published product currently shares the active ingredient and strength of DEXTROAMP-AMPHETAMIN 10 MG TAB in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures DEXTROAMP-AMPHETAMIN 10 MG TAB?
DEXTROAMP-AMPHETAMIN 10 MG TAB (NDC 68462064901) is labeled by Glenmark Pharmaceuticals Inc., USA, and CMS classifies it as a generic product.